In a previous post have talked about the fascinating concept of epigenetics. You can read it here.
There are four drugs approved which target the epigenetic mechanism. Two drugs are in, MDS, myelodysplastic syndrome named 5-azacitidine and decitabine. They marginally improve the survival and do have myelosuppression as toxicity but have scope for further refinement and improvement.
The other two drugs are Vorinostat and Romidepsin, HDAC inhibitors (histone deacetylase) approved in Cutaneous T Cell Lymphoma (CTCL).
Better understanding of acetylation, methylation in cancer. Better targeting by newer drugs. Possible combination therapies limiting toxicity but improving efficacy are much needed in the use of these new drugs.
For those interested to know in detail..
Ref: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3615839/
There are four drugs approved which target the epigenetic mechanism. Two drugs are in, MDS, myelodysplastic syndrome named 5-azacitidine and decitabine. They marginally improve the survival and do have myelosuppression as toxicity but have scope for further refinement and improvement.
The other two drugs are Vorinostat and Romidepsin, HDAC inhibitors (histone deacetylase) approved in Cutaneous T Cell Lymphoma (CTCL).
Better understanding of acetylation, methylation in cancer. Better targeting by newer drugs. Possible combination therapies limiting toxicity but improving efficacy are much needed in the use of these new drugs.
For those interested to know in detail..
Ref: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3615839/
HDACI from Vahid Nikouei
No comments:
Post a Comment